AlphaFold’s recent advancements and its potential impact on predictive medicine

AI in Precision Oncology  shared a post on X:

“AIPO is excited to publish a new Review article.

Vivek Subbiah and his coauthors explore AlphaFold’s recent advancements and its potential impact on predictive medicine. Read the article and the new June issue today!”

Vivek Subbiah shared this post, adding:

“Over the past three decades, genomic medicine has undergone a transformative journey driven by groundbreaking technologies such as the Human Genome Project and CRISPR-Cas9.

Now, artificial intelligence (AI) has taken center stage with AlphaFold, a remarkable example of AI’s computational capabilities in predicting protein structures. In this review, we explore into AlphaFold’s recent advancements and explore its potential impact on predictive medicine.

The latest iteration of AlphaFold represents a major milestone in structural biology, showcasing AI’s unprecedented ability to accurately predict intricate protein structures.

This shift toward predictive medicine envisions an era where AI, integrated with genomic data, revolutionizes our understanding of diseases, facilitates drug design, and enables personalized therapeutics.”

Sources: AI in Precision Oncology/X and Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cance.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.